Comparison of serum acylcarnitine levels in patients with myalgic encephalomyelitis/chronic fatigue syndrome and healthy controls: a systematic review and meta-analysis. — CFSMEATLAS
Comparison of serum acylcarnitine levels in patients with myalgic encephalomyelitis/chronic fatigue syndrome and healthy controls: a systematic review and meta-analysis.
Jinushi, Ryuhei, Masuda, Sakue, Tanisaka, Yuki et al. · Journal of translational medicine · 2023 · DOI
Quick Summary
This review combined results from seven studies comparing a chemical in the blood called acylcarnitine between people with ME/CFS and healthy people. Researchers found that people with ME/CFS have significantly lower levels of this chemical. These lower levels might one day help doctors diagnose ME/CFS, though more research is needed before it can be used as a reliable test.
Why It Matters
ME/CFS currently lacks a definitive diagnostic test, forcing doctors to rely solely on clinical symptoms, which delays diagnosis and causes frustration for patients. This review provides evidence that a simple blood test measuring acylcarnitine could potentially help confirm ME/CFS alongside clinical evaluation, bringing the field closer to objective diagnostic tools. For researchers, this finding highlights a consistent biological marker that warrants further investigation into the metabolic dysfunction underlying ME/CFS.
Observed Findings
Serum acylcarnitine levels were significantly lower in ME/CFS patients compared to healthy controls across the analyzed studies
The meta-analysis included 403 ME/CFS patients evaluated across seven studies
High statistical heterogeneity was observed between studies
The analysis included data from PubMed and Ichushi-Web databases through February 17, 2023
Inferred Conclusions
Low serum acylcarnitine levels represent a consistent biological difference between ME/CFS patients and healthy controls
Measurement of acylcarnitine, combined with clinical symptoms, may have future utility as a diagnostic biomarker for ME/CFS
Further research is needed to validate acylcarnitine testing as a standardized diagnostic tool
Remaining Questions
Do acylcarnitine levels correlate with disease severity or specific ME/CFS symptoms, and can they predict treatment response?
What causes acylcarnitine levels to be low in ME/CFS, and does this reflect broader metabolic dysfunction in energy production?
How many acylcarnitine subtypes should be measured, and what cutoff values would best distinguish ME/CFS patients from healthy controls and other conditions?
What This Study Does Not Prove
This study does not establish that acylcarnitine testing alone can diagnose ME/CFS or that it should replace clinical criteria. It also does not determine whether low acylcarnitine causes ME/CFS symptoms or simply occurs alongside the disease. The high heterogeneity between studies suggests that factors like patient populations, disease severity, or measurement methods may significantly affect results, limiting how broadly these findings apply.
Will larger, prospective studies with standardized measurement methods reduce the high heterogeneity and establish acylcarnitine as a clinically useful diagnostic test?